RAPP
Rapport Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$1.46B
5Y Perf.+71.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RAPP vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.+299.8%
RAPP vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RAPP | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.46B | $1712.35T |
| Revenue (TTM) | $20M | $0.00 |
| Net Income (TTM) | $-107M | $-168M |
| Gross Margin | -1.3% | — |
| Operating Margin | -6.1% | — |
| Total Debt | $11M | $22M |
| Cash & Equiv. | $53M | $194M |
RAPP vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RAPP
DBVT
| Stock | Jun 24 | May 26 | Return |
|---|---|---|---|
| Rapport Therapeutic… (RAPP) | 100 | 171.7 | +71.7% |
| DBV Technologies S.… (DBVT) | 100 | 399.8 | +299.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RAPP vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RAPP leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
RAPP
Rapport Therapeutics, Inc. Common Stock
The Growth Play
RAPP carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 24.3%
- 92.0% 10Y total return vs DBVT's -87.0%
- Lower volatility, beta 1.55, Low D/E 2.4%, current ratio 26.17x
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 1.26
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs RAPP's -5.4%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RAPP | -20.9% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs RAPP's -5.4% |
| Stability / Safety | DBVT | Beta 1.26 vs RAPP's 1.55 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RAPP | +290.7% vs DBVT's +110.4% |
| Efficiency (ROA) | RAPP | -23.4% ROA vs DBVT's -89.0% |
RAPP vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRAPPLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
RAPPRapport Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RAPP5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RAPP6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RAPP and DBVT operate at a comparable scale, with $20M and $0 in trailing revenue.
| Metric | RAPPRapport Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $20M | $0 |
| EBITDAEarnings before interest/tax | -$121M | -$112M |
| Net IncomeAfter-tax profit | -$107M | -$168M |
| Free Cash FlowCash after capex | -$80M | -$151M |
| Gross MarginGross profit ÷ Revenue | -1.3% | — |
| Operating MarginEBIT ÷ Revenue | -6.1% | — |
| Net MarginNet income ÷ Revenue | -5.4% | — |
| FCF MarginFCF ÷ Revenue | -4.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +38.2% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RAPP and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RAPPRapport Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $1.5B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -13.96x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 3.87x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RAPP and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RAPP leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
RAPP delivers a -24.8% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-130 for DBVT. RAPP carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs RAPP's 2/9, reflecting mixed financial health.
| Metric | RAPPRapport Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -24.8% | -130.2% |
| ROA (TTM)Return on assets | -23.4% | -89.0% |
| ROICReturn on invested capital | -27.1% | — |
| ROCEReturn on capital employed | -31.3% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x |
| Net DebtTotal debt minus cash | -$41M | -$172M |
| Cash & Equiv.Liquid assets | $53M | $194M |
| Total DebtShort + long-term debt | $11M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
RAPP leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RAPP leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RAPP five years ago would be worth $19,197 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, RAPP leads with a +290.7% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors RAPP at 24.3% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | RAPPRapport Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +42.0% | +4.9% |
| 1-Year ReturnPast 12 months | +290.7% | +110.4% |
| 3-Year ReturnCumulative with dividends | +92.0% | +19.7% |
| 5-Year ReturnCumulative with dividends | +92.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | +92.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +24.3% | +6.2% |
RAPP leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RAPP and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than RAPP's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPP currently trades 94.5% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RAPPRapport Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 1.26x |
| 52-Week HighHighest price in past year | $42.27 | $26.18 |
| 52-Week LowLowest price in past year | $7.73 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +94.5% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 61.9 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 335K | 252K |
Evenly matched — RAPP and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RAPP as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.7% for RAPP (target: $49).
| Metric | RAPPRapport Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $49.00 | $46.33 |
| # AnalystsCovering analysts | 5 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RAPP leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallRapport Therapeutics, Inc. … (RAPP)Leads 2 of 6 categories
Loading custom metrics...
RAPP vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RAPP or DBVT a better buy right now?
Analysts rate Rapport Therapeutics, Inc.
Common Stock (RAPP) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RAPP or DBVT?
Over the past 5 years, Rapport Therapeutics, Inc.
Common Stock (RAPP) delivered a total return of +92. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: RAPP returned +92. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RAPP or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Rapport Therapeutics, Inc. Common Stock's 1. 55β — meaning RAPP is approximately 23% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Rapport Therapeutics, Inc. Common Stock (RAPP) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — RAPP or DBVT?
On earnings-per-share growth, the picture is similar: Rapport Therapeutics, Inc.
Common Stock grew EPS 24. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RAPP or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -536. 4% for Rapport Therapeutics, Inc. Common Stock — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -611. 0% for RAPP. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RAPP or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RAPP or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Rapport Therapeutics, Inc. Common Stock (RAPP) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, RAPP: +92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RAPP and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.